Lineage Cell Therapeutics, Inc. (TLV:LCTX)

Lineage Cell Therapeutics Ratios and Metrics

Market cap in millions ILS. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 8, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,306	403	687	699	1,284	849
Market Cap Growth	194.41%	-41.27%	-1.77%	-45.56%	51.35%	84.30%
Enterprise Value	1,183	289	544	471	1,087	732
Last Close Price	5.82	1.86	3.91	3.92	7.74	5.59
PS Ratio	36.48	11.66	21.32	13.53	95.13	144.57
PB Ratio	18.97	1.44	3.08	2.77	4.54	2.78
P/TBV Ratio	-	5.23	30.84	12.45	11.89	6.86
P/FCF Ratio	-	-	-	307.85	-	-
P/OCF Ratio	-	-	-	187.79	-	-
EV/Sales Ratio	34.70	8.36	16.88	9.11	80.50	124.70
EV/FCF Ratio	-17.12	-	-	207.31	-	-
Debt / Equity Ratio	0.13	0.03	0.05	0.05	0.03	0.04
Debt / FCF Ratio	-	-	-	6.03	-	-
Asset Turnover	0.12	0.09	0.08	0.10	0.03	0.02
Quick Ratio	4.33	3.47	2.02	3.07	2.32	5.35
Current Ratio	4.50	3.65	2.14	3.16	2.37	5.66
Return on Equity (ROE)	-157.75%	-26.73%	-32.07%	-32.37%	-46.52%	-20.05%
Return on Assets (ROA)	-13.65%	-12.53%	-11.80%	-9.44%	-21.77%	-14.16%
Return on Capital (ROIC)	-27.95%	-18.58%	-18.82%	-16.61%	-31.93%	-15.35%
Return on Capital Employed (ROCE)	-25.30%	-21.60%	-25.50%	-21.50%	-38.60%	-26.40%
Earnings Yield	-17.15%	-16.80%	-11.27%	-13.21%	-10.42%	-7.82%
FCF Yield	-5.29%	-21.36%	-15.33%	0.33%	-5.79%	-7.51%
Buyback Yield / Dilution	-25.54%	-15.94%	-1.69%	-3.22%	-9.64%	-3.10%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.